Showing results (211-220 of 332) with videos related to

Sort By:
Pageof 34
Transplantation|November 4, 2015
Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie CellulaireAurelie Ravinet, Aurelie Cabrespine, Gerard Socié, et al.
Bone Marrow Transplantation|December 19, 2020
Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC studyDavid Beauvais, Elodie Drumez, Didier Blaise, et al.
Cancer Medicine|September 21, 2021
Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamideMaxime Jullien, Corentin Orvain, Ana Berceanu, et al.
American Journal of Hematology|January 2, 2024
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamideMaxime Jullien, Thierry Guillaume, Amandine Le Bourgeois, et al.
European Journal of Haematology|January 26, 2017
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemiaXavier Cahu, Martin Carré, Christian Recher, et al.
Bone Marrow Transplantation|May 5, 2023
Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMTKlaus Hirschbühl, Myriam Labopin, Emmanuelle Polge, et al.
Leukemia|February 5, 2021
Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMTJordi Esteve, Sebastian Giebel, Myriam Labopin, et al.
Transplantation and Cellular Therapy|August 28, 2022
Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid LeukemiaArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
Haematologica|April 9, 2016
Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working PartyRaynier Devillier, Jean-Hugues Dalle, Austin Kulasekararaj, et al.
Leukemia|December 22, 2022
Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity mattersPeter-Martin Bruch, Sascha Dietrich, Herve Finel, et al.
Pageof 34